Janku, Filip http://orcid.org/0000-0002-8123-4065
LoRusso, Patricia
Mansfield, Aaron S.
Nanda, Rita
Spira, Alexander
Wang, Tianli
Melhem-Bertrandt, Amal
Sugg, Jennifer
Ball, Howard A.
Funding for this research was provided by:
Astellas Pharma, Inc
Article History
Received: 30 January 2021
Accepted: 30 March 2021
First Online: 8 April 2021
Declarations
:
: Dr Filip Janku reports grants from Novartis, Genentech, BioMed Valley Discoveries, Plexxikon, Deciphera, Piqur, Symphogen, Bayer, FujiFilm Corporation, Astex, Asana, Astellas, Agios, Proximagen, and Bristol-Myers Squibb; and other support from Deciphera, IFM Therapeutics, Synlogic, Guardant Health, Ideaya, PureTech Health, Jazz Pharmaceuticals, Trovagene, Immunomet, Primmune Therapeutics, and Sotio, outside the submitted work.Dr Patricia LoRusso reports honorarium from advisory boards from AbbVie, Agios, GenMab, Genentech, CytomX, Takeda, Cyrexa, Agenus, IQVIA, TRIGR, Pfizer, I-MAB, ImmunoMet, Black Diamnod, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics; and has been a consultant for Five Prime, Halozyme, Roche-Genentech, SOTIO, and Tyme.Dr Aaron Mansfield has no direct conflicts, but reports research support from Bristol-Meyers Squibb, Novartis, and Verily, remuneration to his institution for participation on advisory boards for AbbVie, Astra Zeneca, BMS, and Genentech, and is a non-remunerated director of the Mesothelioma Applied Research Foundation. Dr Rita Nanda reports personal fees from Aduro, grants and personal fees from AstraZeneca, personal fees from Athenex, grants and personal fees from Celgene, personal fees from Daiichi Sankyo, grants and personal fees from Genentech, personal fees from Macrogenics, grants and personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Puma, personal fees and other from G1 Therapeutics, other from OBI Pharma, grants from Immunomedics, grants from Odonate, and grants from Seattle Genetics, outside the submitted work. Dr Alexander Spira reports grants and non-financial support from Astellas during the conduct of the study; grants, personal fees, and non-financial support from Cytomx; grants, personal fees, and non-financial support from AstraZeneca; and non-financial support from Roche, outside the submitted work.Dr Tianli Wang has nothing to disclose. Dr Amal Melhem-Bertrandt was an employee of Astellas at the time of the study. Jennifer Sugg is an employee of Astellas and holds stock in AstraZeneca. Dr Howard A. Ball has nothing to disclose.
: The study was conducted in accordance with Good Clinical Practice, the International Council for Harmonisation, and guidelines governing clinical study conduct and the ethical principles originating from the Declaration of Helsinki.The study was approved by the respective Institutional Review Boards.
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable.